More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$26.73B
EPS
-2.83
P/E ratio
--
Price to sales
19.31
Dividend yield
--
Beta
0.82516
Previous close
$122.88
Today's open
$122.80
Day's range
$118.44 - $123.32
52 week range
$90.39 - $212.75
show more
CEO
William H. Lewis
Employees
1664
Headquarters
Bridgewater, NJ
Exchange
Nasdaq Global Select
Shares outstanding
219380309
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead
Insmed NASDAQ: INSM expects its bronchiectasis drug BRINSUPRI to generate $1.35 billion to $1.4 billion in its first full year of launch, Chief Executive Officer Will Lewis said, as the company looks to reach more patients and expand its pipeline.
MarketBeat • Nov 17, 2026

Insmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Insmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
Zacks Investment Research • Nov 10, 2026

Insmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance
Insmed Incorporated is rated Hold, with a fair value of ~$99 versus a $110 share price, reflecting a blockbuster BRINSUPRI launch. INSM's valuation assumes BRINSUPRI sustains ~$75M quarterly sales growth for three years, exceeding the company's Q4 midpoint guidance. Key catalysts are Q4 2026 BRINSUPRI sales and the January 2027 FDA decision on ARIKAYCE's label expansion; either could shift the rating.
Seeking Alpha • Nov 7, 2026

Insmed to Present at November and December 2026 Investor Conferences
BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 2:00 p.m.
PRNewsWire • Nov 4, 2026

INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
Zacks Investment Research • Oct 30, 2026

Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript
Insmed Incorporated ( INSM ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants William Lewis - President, CEO & Chairman Sara Bonstein Martina Flammer - Chief Medical Officer Conference Call Participants Yesha Patel - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Faisal Khurshid - Jefferies LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Ritu Baral - TD Cowen, Research Division Jason Zemansky - BofA Securities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Maxwell Skor - Morgan Stanley, Research Division Leonid Timashev - RBC Capital Markets, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the Insmed Third Quarter 2026 Financial Results Conference Call.
Seeking Alpha • Oct 31, 2026

What Insmed (INSM) Said on Its Q3 Earnings Call
Insmed NASDAQ: INSM reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE.
MarketBeat • Oct 29, 2026

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of 2026— —ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $124.4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of 2025— —Company Raises 2026 BRINSUPRI Revenue Guidance to $1.35 Billion to $1.4 Billion— —Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million— — Insmed Launches BRINSUPRI Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan— BRIDGEWATER, N.J., Oct. 29, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
PRNewsWire • Oct 29, 2026

Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Insmed Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.